Safety and Tolerability of Metronidazole Gel 1.3%

NCT02392026 | Completed Phase 4

• 1 other identifier: MG1401
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 8

Brief Summary

Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel in females 12 to \<18 years for the treatment of bacterial vaginosis.

Conditions

Vaginosis, Bacterial

Outcome Measures

Primary Outcomes (2)

• Number of subjects with treatment-emergent adverse events (AEs), serious AEs, treatment-related AEs and AEs leading to study discontinuation after Metronidazole Vaginal Gel is administered in post-menarcheal, adolescent females with bacterial vaginosis.

  No serious AEs reported during the completed study

  up to 10 days

• A multicenter open label to evaluate safety and tolerability of metronidazole vaginal gel 1.3% for adolescents female subject with bacterial and vaginosis

  Metronidazole Vaginal Gel 1.3% is safe, well tolerated, and efficacious in treating vaginal discharge and odor in adolescent females aged 12 to \< 18 years with bacterial vaginosis. The safety and efficacy profiles in this study were consistent with the known safety and efficacy profiles for the adult population and no new safety concerns were identified.

  up tp 10 days

Secondary Outcomes (1)

• Number of subjects reporting presence of daily vaginal discharge and/or odor following single dose administration of Metronidazole Vaginal Gel 1.3%assessment of the presence of vaginal discharge and odor following single dose administration.

  up to 10 days

Study Arms (1)

Metronidazole Gel

EXPERIMENTAL

Metronidazole Vaginal Gel

Drug: Metronidazole Gel

Interventions

Metronidazole Gel DRUG

Metronidazole Vaginal Gel 1.3% administered via applicator

Also known as: Metro Gel

Metronidazole Gel

Eligibility Criteria

• Age: 12 Years - 17 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Provide written assent and parent/legal guardian informed consent and authorization to disclose protected health information.
• Post-menarcheal, adolescent female, 12 to \<18 years of age at time of Screening/Baseline Visit (Day 1).
• In good general health at Screening visit with no known medical conditions that, in the Investigator's opinion, may interfere with study participation.
• Has negative urine pregnancy test result prior to study treatment initiation.
• Has clinical diagnosis of bacterial vaginosis.
• Agree to abstain from sexual intravaginal intercourse for study duration.
• Willing to avoid alcohol ingestion for 24 hours after administration of test article.
• Agree to refrain from use of intravaginal products for duration of study (e.g. lubricated condoms, tampons, diaphragms, spermicides, feminine deodorant sprays, douches). Intravaginal Uterine Device (IUD) use is acceptable as long as it has been in place for 30 days prior to study enrollment.
• Willing and able to participate in study, make required visits to the study center, and comply with all study requirements including concomitant medication and other treatment restrictions.

You may not qualify if:

• Pregnant, lactating, or planning to become pregnant during study period.
• Currently menstruating or anticipate onset of menses during first 9 days of the study.
• Experience a clinically important medical event with 90 days of Screening/Baseline Visit (Day 1).
• Evidence of other infectious causes of vulvovaginal infection or condition that in the Investigator's opinion would confound the interpretation of the study results.
• Severe symptoms of dysuria and/or pruritus, burning or irritation in vulvovaginal area.
• Received systemic or intravaginal antifungal, antibacterial or antiparasitic drugs within 14 days of Screening/Baseline visit (Day 1). Antiviral therapies (non-intravaginal) are acceptable.
• Has taken disulfiram or systemic corticosteroids (oral or injected) within 14 days of Screening/Baseline Visit (Day 1).
• Had sexual intravaginal intercourse within 24 hours of Screening/Baseline (Day 1).
• Demonstrated previous hypersensitivity to metronidazole, either orally or topically administered, or any form of parabens or benzyl alcohol.
• Known primary or secondary immunodeficiency condition/syndrome.
• Being treated or planning to be treated during the study period for cervical intraepithelial neoplasia (CIN) or cervical carcinoma.
• Using anticoagulation therapy with Coumadin (warfarin).
• Previously treated with test article under this protocol.
• Participate in an experimental drug/device trial within the last 30 days before Screening/Baseline Visit (Day 1).
• Is judged by the Investigator to be unsuitable for any reason.

Sponsors & Collaborators

• Insud Pharma: lead
• Allergan Sales, LLC: collaborator

Study Sites (8)

Allergan Research Site #318

Long Beach, California, 90806, United States

Location

Allergan Research Site #324

Paramount, California, 90723, United States

Location

Allergan Research Site #315

Bardstown, Kentucky, 40004, United States

Location

Allergan Research Site #314

New Orleans, Louisiana, 70115, United States

Location

Allergan Research Site #319

Columbus, Ohio, 43231, United States

Location

Allergan Research Site #322

Dayton, Ohio, 45406, United States

Location

Allergan Research Site #321

Memphis, Tennessee, 38104, United States

Location

Allergan Research Site #316

Irving, Texas, 75062, United States

Location

MeSH Terms

Conditions

Vaginosis, Bacterial

Condition Hierarchy (Ancestors)

Bacterial Infections; Bacterial Infections and Mycoses; Infections; Vaginitis; Vaginal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Study Officials

• Gina Giannantoni-Ibelli, MS

  Allergan

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 4, 2015
• First Posted: March 18, 2015
• Study Start: August 12, 2015
• Primary Completion: October 5, 2016
• Study Completion: October 5, 2016
• Last Updated: August 15, 2023

Record last verified: 2023-08

Locations

US (8)